September 18, 2018 05:11 PM EDT
People

Clo­vis CEO Patrick Ma­haffy set­tles up on SEC charges of ly­ing about the ro­ci da­ta — and it won’t cost much

John Carroll

Editor & Founder

For 4 crit­i­cal months in 2015, Clo­vis $CLVS and its ex­ec­u­tives led by CEO Patrick Ma­haffy main­tained that their can­cer drug ro­ci had per­formed beau­ti­ful­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times